{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:29:53Z","timestamp":1793456993032,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.03.066","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T10:17:11Z","timestamp":1714040231000},"page":"3166-3171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia"],"prefix":"10.1016","volume":"42","author":[{"given":"Ramona","family":"Muttucumaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-4169","authenticated-orcid":false,"given":"Colleen L.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Furuya-Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2024.03.066_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.066_b0010","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1099\/jmm.0.000386","article-title":"Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine","volume":"65","author":"Gabutti","year":"2016","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.066_b0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2024.03.066_b0020","unstructured":"Australian Government DoHaAC. Zostavax. 2018. https:\/\/immunisationhandbook.health.gov.au\/vaccines\/zostavax (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0025","unstructured":"Australian Government DoHaAC. Shingrix. 2022. https:\/\/immunisationhandbook.health.gov.au\/vaccines\/shingrix (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0030","unstructured":"Australian Immunisation Handbook. Zoster (herpes zoster). 2023. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/zoster-herpes-zoster (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0035","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.vaccine.2024.03.066_b0040","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.066_b0045","unstructured":"Australian Government DoHaAC. National Immunisation Program \u2013 changes to shingles vaccination from 1 November 2023. 2023. https:\/\/www.health.gov.au\/news\/national-immunisation-program-changes-to-shingles-vaccination-from-1-november-2023 (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0050","unstructured":"Centers for Disease Control and Prevention. Shingles Vaccination. 2023. https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/public\/shingrix\/index.html (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0055","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. 2023. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0060","unstructured":"Administration; USFD. SHINGRIX. 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0065","unstructured":"GSK. Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over. 2018. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over\/ (accessed Dec 2023 2023)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0070","unstructured":"Therapeutic Goods Administration. SHINGRIX (GlaxoSmithKline Australia Pty Ltd). 2018. https:\/\/www.tga.gov.au\/resources\/prescription-medicines-registrations\/shingrix-glaxosmithkline-australia-pty-ltd (accessed Dec 2023 2023)."},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.066_b0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/aje\/kwac170","article-title":"Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data","volume":"192","author":"Nelson","year":"2023","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.066_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (shingrix) - United States, october 2017-june 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"10.1016\/j.vaccine.2024.03.066_b0085","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.066_b0090","unstructured":"Leeb A. SmartVax. 2009. https:\/\/www.smartvax.com.au\/ (accessed Feb 2021."},{"key":"10.1016\/j.vaccine.2024.03.066_b0095","unstructured":"Leeb A. SmartVax perticipating clinics. 2009. https:\/\/www.smartvax.com.au\/smartvax-participating-clinics\/ (accessed online June 2021)."},{"key":"10.1016\/j.vaccine.2024.03.066_b0100","unstructured":"AusVax Safety. Shingrix\u00ae safety data \u2013 all participants. 2023. https:\/\/ausvaxsafety.org.au\/shingrixr\/shingrixr-safety-data-all-participants (accessed Dec 2023 2023)."},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.066_b0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 Years: recommendations of the Advisory committee on immunization Practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.03.066_b0110","unstructured":"Centers for Disease Control and Prevention. Shingrix Recommendations. 20https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/recommendations.html (accessed Dec 2023 2023)."},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.066_b0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jech-2019-213435","article-title":"Do men avoid seeking medical advice? a register-based analysis of gender-specific changes in primary healthcare use after first hospitalisation at ages 60+ in Denmark","volume":"74","author":"H\u00f6hn","year":"2020","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.066_b0120","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/STROKEAHA.120.032788","article-title":"Herpes zoster vaccine live and risk of stroke among medicare beneficiaries: a population-based cohort study","volume":"52","author":"Yang","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.066_b0125","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 syndrome following recombinant zoster vaccine in medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.066_b0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5694\/mja13.11166","article-title":"Using automated text messages to monitor adverse events following immunisation in general practice","volume":"200","author":"Leeb","year":"2014","journal-title":"Med J Aust"},{"issue":"36","key":"10.1016\/j.vaccine.2024.03.066_b0135","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:35:04Z","timestamp":1760816104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X24003724"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}